Risperidone Response: Therapeutic Complications from Genetic Variation in Cytochrome P450-2D6 Expression

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/0012/31/03

Funding

  • Eli Lilly and Company: $265,525.00